和黄医药(00013)于2026年4月1日披露2026年3月的股份变动月报表。公告显示，截至2026年3月31日，公司法定股本维持在15亿股，面值0.1美元，总额1.5亿美元，较上月底无任何增减变动。
公司已发行股份数量维持872,327,620股，与上月底保持一致，期间未发生新增发行、购回或注销行为，也无库藏股变动。公告提到，基于2015年4月24日通过的认股权计划，本月内有1,359,561份期权失效，但并未导致公司普通股本增加或减少。截至本月底，相关项下尚余24,287,372份在有效期内的期权。
公告确认公司目前符合香港联交所关于上市公司公众持股量的要求。公司同时声明，已遵照相关上市规则及适用法律规定履行披露义务。该公告由公司非执行董事兼公司秘书施熙德签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.